Chinese pharmaceutical and biotech companies are increasingly shifting from generic drug production to pioneering cutting-edge, innovative oncology and immunology treatments. Western big pharma giants are responding by aggressively licensing promising drug assets from Chinese developers rather than relying solely on internal pipelines. This trend is dramatically shortening development timelines and altering how global pharmaceutical companies approach research and development investments. U.S. lawmakers and regulatory bodies are simultaneously scrutinizing these cross-border partnerships, weighing potential national security and supply chain implications. Ultimately, this intense global competition is reshaping the pharmaceutical landscape, driving down costs, and accelerating the delivery of breakthrough therapies to patients worldwide.

Full report : Chinese biotech firms are challenging Western pharmaceutical giants by accelerating drug discovery, licensing innovative therapies abroad, and forcing a strategic rethink across the industry.